Personal Genome Diagnostics (PGDx) received a new contract from the U.S. Department of Veterans Affairs to provide a test for cancer that does not require tissue samples.
The Canton-based company makes a liquid biopsy, which tests for cancer by evaluating 64 genes that are associated with cancer.
The test can be conducted through a blood test, rather than obtaining tissue samples through a traditional biopsy or conducting an ultrasound. The test can also be conducted multiple times during treatment, providing a “real-time livestream of what’s happening at the genetic level in the patient’s tumor or tumors,” PGDx Manager for Translational Science and Diagnostics John Simmons told Technical.ly last year.
The test will be offered to advanced cancer patients who are receiving treatment in the VA, according to the company.
The company’s work on liquid biopsy got attention from the White House last year, when Vice President Joe Biden included PGDx among the group of experts working on the Cancer Moonshot.
The new contract is an expansion of work with the VA for PGDx, which was founded by Johns Hopkins researchers. PGDx also has a contract to provide its product which analyzes tumors on the genetic level.
The company raised a $21.4 million Series A in 2015.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
Donate to the Journalism Fund
Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.

These 10 regions could be most impacted by federal return-to-office mandates

From Belgaum to Baltimore and beyond, this founder leaned on family to build a biotech juggernaut

Tech-related orders and economic reorganizations hit Maryland. Here’s what they mean.
